Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

Abstract

Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B-cell defects.